Sumanta Kumar Pal, MD, FASCO, presents the case of a 66-year-old man with metastatic renal cell carcinoma, and the panel provides comprehensive insights on treatment decisions, highlighting the NCCN Guidelines.
Rana R. McKay, MD
Rana R. McKay, MD, is a board-certified medical oncologist who specializes in treating people with urogenital cancers at UC San Diego Health.
Articles by Rana R. McKay, MD
A panel of 4 experts on renal cell carcinoma introduce themselves and discuss IMDC risk stratification criteria and the evolution of the treatment landscape.
Following their program on data updates in GU cancer from ESMO 2023, Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, share key takeaways from SunRISe-1, EV-302, and PSMAfore.
Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Shifting their focus to metastatic bladder cancer, the Oncology Brothers and Rana McKay, MD, reflect on data from EV-302 and consider how enfortumab vedotin + pembrolizumab has shifted the treatment landscape.
Key opinion leader Rana McKay, MD, joins the Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, to review updated data in GU cancer from ESMO 2023, starting with TAR-200 monotherapy in patients with NMIBC and the SunRISE-1 trial.
Concluding the discussion, Dr Rana McKay discusses the current state of advanced RCC, potential breakthroughs, and best practices for optimal patient outcomes.
Rana McKay, MD, provides insights into decision-making strategies and consideration for treatment sequencing in advanced RCC.
Discussion on triplet therapy regimens in advanced RCC and how progressing therapeutic studies can impact its future use.
Expert perspective on CheckMate 9ER quality of life data and treatment implications for patients with advanced RCC.
Centering discussion on the CheckMate 9ER trial, Dr. McKay shares perspective of recent follow-up data of nivolumab + cabozantinib in frontline advanced RCC.
Reflection on biomarkers, treatment resistance, and other unmet needs in 1L treatment of advanced RCC by Rana R. McKay, MD.
Dr Rana McKay provides insight on preferred therapeutic options for first-line treatment of RCC and how patient risk stratification influences decision making.
Rana R. McKay, MD, reflects on the landscape of advanced RCC, discusses histology, subsets of kidney cancer, and IMDC criteria for prognostic stratification.
Expert genitourinary oncologists close their discussion with advice to community oncologists treating renal cell carcinoma.
A panel of experts on renal cell carcinoma discuss triplet therapy and review COSMIC-313, a study of cabozantinib, nivolumab, and ipilimumab in the first line.
Expert oncologists discuss the management of immune-related adverse events in renal cell carcinoma.
An overview of adverse event and toxicity considerations with TKI therapies in renal cell carcinoma.
Expert oncologists review data updates on IO-IO regimens in the treatment of advanced RCC, including CheckMate 214, and discuss treatment selection among IO-IO and IO-TKI combinations.
Multidisciplinary experts discuss the role of concurrent radiation in the treatment of renal cell carcinoma.
A panel of experts in renal cell carcinoma present the case of a 59-year-old woman with renal cell carcinoma and discuss systemic therapy options.
RCC experts discuss second-line therapy options following progression on first-line IO-TKI regimen.
Detailed insights on how the choice of tyrosine kinase inhibitors (TKIs) in IO-TKI regimens impact the treatment of advanced renal cell carcinoma.
Experts on renal cell carcinoma discuss frontline treatment options for favorable-risk disease and factors that impact treatment decisions.
A comprehensive discussion on how to select the appropriate IO-TKI regimen in the frontline setting in advanced renal cell carcinoma.
A panel of experts on renal cell carcinoma review updated data on IO-TKI regimens in advanced RCC, including the CheckMate 9ER, KEYNOTE-526, and CLEAR trials.
Expert oncologists give an overview of molecular testing, risk stratification, and treatment guidelines for renal cell carcinoma.
Rana McKay, MD engages with critical gaps in mCRPC patient care, comments on promising clinical trials, and shares clinical pearls for community oncologists treating patients with mCRPC.
Subject matter expert reviews key trial data from recent years and explains how these data impact the prostate cancer treatment landscape.
Dr McKay shares her initial impressions of an mCRPC patient case before discussing typical patient treatment protocols, NCCN guidelines, and standard therapeutic options.